Angiotensin II AT1 수용체 길항제인 SK-1080의 적출심장에 대한 허혈후 재관류시의 작용 및 혈소판응집과 혈액응고에 대한 효과

Effects of the AngiotensinII AT1 Receptor Antagonist SK-1080 on Ischemia/reperfusion in Isolated Rat Hearts and on Platelet Aggregation and Coagulation in Human Blood

SK-1080 is one of the newly developed orally active nonpeptide angiotensinII AT1-receptor antagonist that selectively acts at AT1 receptor with high affinity. The cardiac effect on ischemia/reperfusion injury of SK-1080 was compared with those of losartan, a prototype of this class, in isolated rat hearts. Isolated perfused rat heart was pretreated with drug for 10 min and then subjected to global ischemia for 30 min followed by reperfusion with- or without drug for 30 min. The possible additive effect of SK-1080 on the platelet aggregation and coagulation in human blood was also studied. We investigated whether SK-1080 effects the platelet aggregation induced by ADP, a platelet agonist partially dependent on thromboxaneA2. The clotting times in the prothrombin time (PT) and activated partial thromboplastin time (APTT) were also examined in human plasma in vitro as coagulation screening test. SK-1080 improved reperfusion function (LVDP, left ventricular developed pressure; PRP, rate-pressure product) in a dose-dependent manner. SK-1080 reduced ADP-induced platelet aggregation compared with vehicle but less than losartan, and did not affect clotting times.